What Is Happening With Emerson Electric Stock?
Emerson Electric (EMR)’s stock soared over 50%, fueled by a surprising revenue uptick and a sharp P/E multiple jump, despite shrinking profit margins. Amid mixed quarterly results and a UBS upgrade, the market’s shifting tides turned investor eyes—sparking this standout surge. What’s behind the volatility?
Below is an analytical breakdown of stock movement into key contributing metrics.
| 4202025 | 1152026 | Change | |
|---|---|---|---|
| Stock Price ($) | 98.3 | 148.0 | 50.6% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 17,550.0 | 18,015.0 | 2.6% |
| Net Income Margin (%) | 13.7% | 12.7% | -7.4% |
| P/E Multiple | 23.2 | 36.3 | 56.7% |
| Shares Outstanding (Mil) | 568.5 | 562.5 | 1.1% |
| Cumulative Contribution | 50.5% |
So what is happening here? The stock jumped 51%, driven by a 2.6% revenue boost and a 57% surge in its P/E multiple, despite a 7.4% dip in net margin. These shifts set the stage for recent company moves.
Here Is Why Emerson Electric Stock Moved
- Q2 2025 Earnings: Adjusted EPS beat, full-year outlook raised; stock rose 3% premarket.
- Q3 2025 Revenue Miss: EPS beat, but revenue missed forecasts; stock dropped over 8% premarket.
- Q4 2025 Mixed Results: EPS met, revenue missed; cautious 2026 outlook led to a stock decline.
- UBS Upgrade: UBS upgraded stock to ‘Buy’ in Jan 2026, citing growth potential; shares jumped 5.4%.
- Market Weakness: Challenges in European and Chinese markets impacted guidance, causing stock drops.
Our Current Assesment Of EMR Stock
Opinion: We currently find EMR stock unattractive. Why so? Have a look at the full story. Read Buy or Sell EMR Stock to see what drives our current opinion.
Risk: A solid way to gauge risk for EMR is to check its declines during major market shocks. It fell about 41% in the Dot-Com Bubble and dropped over 56% during the Global Financial Crisis. In 2018’s correction and the inflation shock, it dipped around 29%, while the Covid sell-off wiped out about 51%. Even with decent fundamentals, EMR isn’t immune when markets turn sour. Sharp pullbacks happen, so having that in mind is key.
EMR stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.